SST.NYSESystem1, INC

Form 4: System1 CEO Michael Blend Awarded 2.5 Million Stock Appreciation Rights

Sentiment:

SEC Form 4


System1 CEO Michael Blend received 2.5 million stock appreciation rights (SARs) on July 1, 2024, tied to the company's achievement of specific EBITDA targets.

Summary

  • On July 1, 2024, Michael Blend, CEO and Chairman of System1, Inc., was granted 2,500,000 stock appreciation rights (SARs).
  • The SARs were granted under the System1, Inc. 2024 Stock Appreciation Rights Plan, as amended.
  • The exercise price of the SARs is $1.44, which was the Issuer's closing price on July 1, 2024.
  • Upon exercising the SARs, Blend will receive either Class A Common Stock or cash, at the Issuer's discretion.
  • The amount received will be based on the difference between the fair market value of Class A Common Stock on the exercise date and the exercise price of $1.44.
  • The SARs vest in four tranches, each representing 25% of the total grant, upon System1 achieving trailing twelve month Adjusted EBITDA (TTM Adjusted EBITDA) targets of $50 million, $60 million, $70 million, and $80 million after the grant date.
  • The SARs expire on July 1, 2031.

Sentiment

Score: 7

Explanation: The document indicates a positive incentive structure for the CEO, aligning his interests with the company's financial performance. The vesting conditions based on EBITDA targets suggest a focus on profitability. However, the ultimate value depends on the company's future stock price and financial results.

Positives

  • The granting of SARs to the CEO aligns his interests with the company's performance and growth.
  • The vesting conditions based on EBITDA targets incentivize the CEO to drive profitability.
  • The long-term expiration date (July 1, 2031) encourages a long-term focus.

Risks

  • The value of the SARs is dependent on System1's stock price exceeding $1.44.
  • Failure to achieve the EBITDA targets will result in the SARs not vesting.
  • The Issuer has the discretion to settle the SARs in either cash or stock, which could dilute existing shareholders if settled in stock.

Future Outlook

The vesting of the SARs is contingent upon System1 achieving specific TTM Adjusted EBITDA targets, indicating a focus on improving profitability.

Industry Context

Granting stock appreciation rights is a common practice to incentivize executives and align their interests with shareholders. The specific EBITDA targets suggest a focus on improving the company's financial performance.

Comparison to Industry Standards

  • Stock appreciation rights are a common form of executive compensation, often used by companies like Alphabet (Google) and Meta (Facebook) to incentivize performance.
  • The vesting schedule based on EBITDA targets is similar to performance-based equity grants used by companies like Amazon and Microsoft.
  • The specific EBITDA targets would need to be compared to System1's historical performance and industry benchmarks to assess their difficulty and appropriateness.

Stakeholder Impact

  • Shareholders: The SARs incentivize the CEO to increase shareholder value through improved financial performance.
  • Employees: Achieving the EBITDA targets could lead to increased job security and potential bonuses.
  • Management: The CEO is incentivized to achieve the EBITDA targets, which could impact management decisions and strategies.

Key Dates

DateDescription
07/01/2024Date of grant of Stock Appreciation Rights (SARs)
07/01/2024Exercise price of $1.44 is based on the Issuer's closing price on this date
07/01/2031Expiration date of the Stock Appreciation Rights (SARs)
07/03/2024Date of filing of the Form 4

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.